cancer therapeutics Market Research Reports

"...... s unlikely to cede this commanding position anytime soon. In 2018, the global Non-Melanoma Skin Cancer market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. ......"

"...... een discovered that the immune system could be manipulated to influence cancerous cells to destroy itself. Several unmet medical needs for treatment of cancer have encouraged R&D of cancer gene therapy. Various factors, such as increasing prev......"

"...... in stimulates the growth and division of malignant cells. The breast cancer monoclonal antibodies (mAbs) market is one of the fastest-growing segments of the global mAbs market and has gained major research significance among biotech and pharm......"

"...... Cancer Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Ovarian Cancer Therapeutics status, future forecas......"

"...... rmost layer called urothelium or transitional epithelium, composed of epithelium or transitional cells. The availability of targeted therapy will be one of the major factors driving the growth prospects for the market until the end of 2021. Th......"

"...... any symptom but in severe cases it can cause pain during urination and can cause problem during sexual intercourse. Castration resistant prostate cancer is referred to as a prostate cancer that is spread to other parts of body and is resistant to med......"

"...... r, and stromal ovarian tumor are some of the less common types. It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has already got some commercially successful chemoth......"

"...... r sub-types are described: classic, endemic, immunosuppresion therapy-related, and epidemic. Classic KS tends to affect older men, be slow growing, and affect the legs. Endemic KS occurs in young adult males in Africa and can be more aggressive. Immu......"

"...... rapid pace. Non-small cell lung cancer is the most common type of lung cancer that causes mortality and morbidity in both developed and developing countries. The approval of late-stage pipeline products like onartuzumab and necitumumab is expe......"

"...... is yet to receive an approval of the first CAR T-cell therapy for multiple myeloma.  The increasing number of collaborations or licensing agreements between companies and research institute, will induce the involvement of more investors in thi......"